Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 333

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 333
---
 securities 
     -  
     (6,859,432)
  
    Maturity of marketable securities 
     -  
     24,000,000 
  
    Net cash provided by investing activities 
     -  
     17,140,568 

    Cash flows from financing activities: 

    Proceeds from issuance of shares of common stock and warrants 
     5,510,591  
     - 
  
    Issuance costs 
     (762,703) 
     - 
  
    Net cash provided by financing activities 
     4,747,888  
     - 

    Net (decrease) increase in cash and cash equivalents 
     (7,575,300) 
     3,735,253 

    Cash and cash equivalents at beginning of year 
     13,362,053  
     9,626,800 

    Cash and cash equivalents at end of year 
    $5,786,753  
    $13,362,053 

    Noncash investing and financing activities 

    ASC 842 lease renewal option exercise 
    $-  
    $236,506 
  
    Transaction costs in accounts payable and other current liabilities 
    $163,333  
    $-  
  
    Change in accumulated other comprehensive income 
    $-  
    $(96,434)

    Supplemental cash flow disclosures 

    Cash paid for income taxes 
    $1,600  
    $1,600 

See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

F-6

INDAPTUS
THERAPEUTICS, INC.

Notes
to Consolidated Financial Statements

NOTE
1: GENERAL

Indaptus
Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the “Company”),
is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic
solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted
product that activates both innate and adaptive anti-tumor and anti-viral immune responses.

Risks
and uncertainties

The
Company is subject to a number of risks similar to those of other companies of similar size in